Scientific Industries Reports Financial Results for Full Year Ended December 31, 2023 and Launches New VIVID-LITE S Pill Counter
01 Apr 2024
Financial Statement
Investor Conference Call to be held at 11:00 a.m. ET on April 3, 2024
BOHEMIA, NY / ACCESSWIRE / April 1, 2024 / Scientific Industries Inc., (OTCQB:SCND), a life sciences tool provider, and a developer of digitally simplified bioprocessing products, reported financial results for the full year ended December 31, 2023.
Product Highlights:
Bioprocessing Systems Operations to start shipping the new DOTS Multi-Parameter Sensor in the second quarter of 2024.
Benchtop Laboratory Equipment Operations launched the new VIVID Lite-S pill counter, an upgraded version of its popular VIVID-LITE featuring a super-fast counting mechanism at an affordable price.
Revenues from VIVID pill counters increased 37% compared to the twelve months ended December 31, 2022 (unaudited).
Full Year Overview - 12/31/2023 vs. 12/31/2022 (unaudited):
Net revenues were $11.1 million, an increase of $0.2 million, or 9%, versus $10.9 million in the prior year period.
Benchtop Laboratory Equipment sales were $9.7 million, an increase of $0.2 million, or .02%, versus the same prior year period.
Torbal division sales were $3.7 million, an increase of $1.0 million, or 37%, versus the same prior year period.
Genie division sales were $6.0 million, a decrease of $0.8 million, or 15%, versus the same prior year period.
Total operating expenses were $14.4 million, up $1.3 million, or 10%, compared to $13.1 million for the prior year period, due to increased sales and marketing and R&D expenses.
Cash, cash equivalents and investments were $5.7 million, as of December 31, 2023.
Management Discussion
Helena Santos, Chief Executive Officer of Scientific Industries, stated, "2023 was a year of investments as we build the foundation for future growth of the Company. We believe that we are in a very good position to achieve the financial goals we have set for 2024 with the introduction and sales of new products for the innovative DOTS platform in our Bioprocessing Systems Operations. We plan to begin shipping our new products next quarter and we are hopeful for a rebound in the biotech and laboratory equipment industries which had suffered from overstocking in 2023. Additionally, we have implemented cost cutting measures across both operating segments to enhance efficiencies and margins."
John Moore, Chairman of Scientific Industries, said, "The coming decades are predicted to be the Age of Living Machines. In this new era synthetic biology will improve the cost and efficacy of, among other products, lifesaving drugs. In order for these innovations from synthetic biology to make their impact, we need to make a step change reduction in the cost of failure and the speed of success. A leading consulting firm for Fortune 500 clients, estimates the average synthetic biology product scale-up costs $3 million and has a 90% likelihood of failure."
"The DOTS Multiparameter platform promises to reduce the cost of scale-up by more than 30% or $1 million and to cut the time and likelihood of failure by more than 50%. For example, we presented DOTS MPS data at three synthetic biology conferences on our own development of a yeast-based expression system for production of our upcoming glucose sensor. Our scientists demonstrated protein titer increased by 20x, development time of the process was reduced from one year to two weeks at a process development cost reduction of well over 90% versus status quo industry methods."
Mr. Moore concluded, "We have a unique and important contribution to make to the commercial viability of the synthetic biology industry. In the coming quarters, when our new MPS devices high throughput digital data is paired by our customers with their AI models, we expect them to prove essential force multipliers for powering profits and innovations."
Twelve Months Ended 12/31/2023 Financial Review
Net revenues for the year ended December 31, 2023, increased $236,900, or 2.2%, to $11,111,500 from $10,879,700 for year ended December 31, 2022 (unaudited), due principally to increased revenues of the Benchtop Laboratory Equipment operations fueled by higher Torbal product sales primarily as a result of an increase of VIVID pill counter sales, partially offset by decreased Genie brand sales which had benefitted from COVID-related sales.
The Company recorded a loss from continuing operations of $9,089,800 for the year ended December 31, 2023 compared to a loss from continuing operations of $15,629,300 for the year ended December 31, 2022 (unaudited), with the prior year reflecting significant expenses related to impairment of goodwill and full valuation of deferred tax assets.
Conference Call Details
Scientific Industries will conduct a conference call to discuss financial results for the twelve months ended December 31, 2023, on Wednesday, April 3, 2024, at 11:00 A.M. ET. Interested parties can access the conference call by dialing (844) 481-2706 or (412) 317-0662 (international). A webcast of the call will be available on the Company's Investor Relations page at or at .
A replay of the call will be available through April 10, 2024, at (877) 344-7529 or (412) 317-0088 (international), replay access code: 6828114, or for 30 days at .
About Scientific Industries, Inc.
Scientific Industries (OTCQB:SCND), is a life science tool provider. It designs, manufactures, and markets laboratory equipment, including the world-renowned Vortex-Genie® 2 Mixer and Torbal® balances, and bioprocessing systems under the product name Cell Growth Quantifier and Liquid Injection System. Scientific Industries' products are generally used and designed for research purposes in laboratories of universities, hospitals, pharmaceutical companies, medical device manufacturers, and pharmacies. To learn more, visit .
About Scientific Bioprocessing, Inc.
SBI offers solutions for digitally simplified bioprocessing in the life science industry. SBI's DOTS Platform turns the standard shake flask into a smart mini bioreactor by providing modern bioprocessing sensors (for e.g., continuous monitoring of biomass, dissolved oxygen, and fluorescence) and control options (as e.g., automated, parameter-based feeding) along with an innovative software for easy sensor control and data monitoring. SBI is committed to delivering exceptional customer service and is a subsidiary of Scientific Industries Inc. To learn more, visit .
Safe Harbor Statement
Statements made in this press release that relate to future events, performance or financial results of the Company are forward-looking statements which involve uncertainties that could cause actual events, performance or results to materially differ. The Company undertakes no obligation to update any of these statements. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as to the date hereof. Accordingly, any forward-looking statement should be read in conjunction with the additional information about risks and uncertainties set forth in the Company's Securities and Exchange Commission reports, including our annual report on Form 10-K.
Company Contact:
Helena R. Santos
CEO and President
Phone: 631-567-4700
hsantos@scientificindustries.com
info@scientificindustries.com
or:
Joe Dorame
Lytham Partners, LLC
Phone: 602-889-9700
SCND@lythampartners.com
---FINANCIAL TABLES FOLLOW---
SCIENTIFIC INDUSTRIES, INC. AND SUBSIDIARIES
CONDENSED BALANCE SHEETS
31-Dec-23
31-Dec-22
ASSETS
Cash and Cash Equivalents
$
796,100
$
1,927,100
Investment Securities
4,928,700
4,272,100
Other Current Assets
6,615,900
6,790,700
Intangibles Assets and Goodwill
1,365,200
1,878,300
Other Long Term Assets
3,024,600
3,201,000
Total Assets
$
16,730,500
$
18,069,200
LIABILITIES AND STOCKHOLDERS' EQUITY
Current Liabilities
$
1,837,300
$
2,120,400
Long-Term Liabilities
1,007,800
1,156,200
Shareholders' Equity
13,885,400
14,792,600
Total Shareholders' Equity & Liabilities
$
16,730,500
$
18,069,200
SCIENTIFIC INDUSTRIES, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENT OF OPERATIONS AND COMPREHENSIVE LOSS
31-Dec-23
31-Dec-22
30-Jun-22
Revenues
$
11,111,500
$
5,237,800
$
11,400,500
Gross Profit
5,102,000
2,318,100
5,736,700
Operating Expenses
14,361,900
6,455,100
17,280,800
Loss From Operations
(9,259,900
)
(4,137,000
)
(11,544,100
)
Total Other Income, Net
170,100
63,900
262,400
Loss From Continuing Operations Before Income Tax (Benefit)
(9,089,800
)
(4,073,100
)
(11,281,700
)
Total Income Tax Expense
-
-
2,390,800
Loss From Continuing Operations
(9,089,800
)
(4,073,100
)
(13,672,500
)
Gain (Loss) From Discontinued Operations, Net of Tax
3,300
(6,300
)
4,400
Net Loss
(9,086,500
)
(4,079,400
)
(13,668,100
)
Comprehensive Gain (Loss)
27,000
97,200
(96,400
)
Total Comprehensive Loss
$
(9,059,500
)
$
(3,982,200
)
$
(13,764,500
)
Basic and Diluted Loss Per Common Share:
Continuing Operations
$
(1.27
)
$
(0.58
)
$
(2.06
)
Discontinued Operations
$
-
$
-
$
-
Consolidated Operations
$
(1.27
)
$
(0.58
)
$
(2.06
)
Weighted average number of outstanding shares (basic):
10,145,211
7,003,599
6,637,471
SOURCE: Scientific Industries, Inc.
View the original press release on accesswire.com
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Indications
-Targets
-Drugs
-Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.